Phase I/II trial of Autologous Platelet Integrated Concentration (APIC) cell-free system for the rapid preparation of concentrated protease inhibitor alpha-2-macroglobulin (A2M) for the treatment of mild to moderate osteoarthritis of the knee

Trial Profile

Phase I/II trial of Autologous Platelet Integrated Concentration (APIC) cell-free system for the rapid preparation of concentrated protease inhibitor alpha-2-macroglobulin (A2M) for the treatment of mild to moderate osteoarthritis of the knee

Planning
Phase of Trial: Phase I/II

Latest Information Update: 25 May 2015

At a glance

  • Drugs Alpha 2-macroglobulin (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 25 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top